<DOC>
	<DOCNO>NCT01723384</DOCNO>
	<brief_summary>Naltrexone , Âµ-opioid receptor antagonist , promise agent methamphetamine-using binge-drinking men sex men ( MSM ) . Naltrexone show efficacy reduce relapse amphetamine FDA-approved alcohol dependence . Oral naltrexone inexpensive toxicity standard daily regimen naltrexone problematic patient forget take medication . Given challenge daily dose , alternate regimen schedule propose increase efficacy expand population may benefit pharmacologic agent . One approach intermittent target administration naltrexone , whereby individual take medication as-needed anticipation substance use period crave . Administration naltrexone prior exposure amphetamine significantly attenuate crave target naltrexone show efficacy reduce heavy alcohol use . However , study assess intermittent target dose naltrexone among methamphetamine-using binge-drinking MSM . Polysubstance use pattern common among MSM , study among abuse one substance urgently need . The aim study determine whether targeted dose naltrexone feasible , tolerable acceptable among non-dependent methamphetamine-using binge-drinking MSM .</brief_summary>
	<brief_title>Intermittent Naltrexone Among Polysubstance Users</brief_title>
	<detailed_description />
	<mesh_term>Naltrexone</mesh_term>
	<criteria>1. male gender transgender maletofemale 2. selfreported anal sex men prior six month influence meth and/or alcohol 3. selfreported meth use least biweekly prior three month 4. least weekly binge drinking ( five drink single drinking session ) prior three month 4 ) interested reduce meth use and/or binge drink 5 ) HIVnegative rapid test medical record HIV infection 6 ) current acute illness require prolong medical care 7 ) chronic illness likely progress clinically trial participation 8 ) able willing provide inform consent adhere visit schedule 9 ) age 1870 year 10 ) baseline complete blood count ( CBC ) , total protein , albumin , glucose , alkaline phosphatase , creatinine , blood urea nitrogen ( BUN ) , electrolytes without clinically significant abnormality determine study clinician conjunction symptom , physical exam , medical history 1. psychiatric ( e.g. , depression suicidal ideation ) medical condition would preclude safe participation protocol 2. know allergy previous adverse reaction naltrexone 3. current use dependence opioids know medical condition currently require may likely require opioid analgesic 4. opioidpositive urine test enrollment 5. current cluster differentiation 4 ( CD4 ) count &lt; 200 cells/mm3 6. moderate severe liver disease ( aspartate aminotransferase , alanine aminotransferase , total bilirubin &gt; 3 time upper limit normal ) 7. impaired renal function ( creatinine clearance &lt; 60 ml/min ) 8. currently participate another research study 9. meth alcohol dependence determine Structured Clinical Interview Diagnostic Statistical Manual Mental Disorders ( SCID ) criteria 10. condition , principal investigator and/or study clinician 's judgment interfere safe participation adherence study procedure . 11. unwillingness provide minimum locator information 12. cellular phone send receive text message 13. plan leave Bay Area study followup 14. comfortable speak read English , enough participate program English</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>methamphetamine</keyword>
	<keyword>alcohol</keyword>
	<keyword>HIV</keyword>
	<keyword>sexual behavior</keyword>
</DOC>